A 6-year-old girl, identified as Mei, died from a severe immune reaction seven days after receiving an experimental gene-editing therapy aimed at correcting a mutation in her brain. The trial, led by neuroscientist Zilong Qiu at Xinhua Hospital in Shanghai, was a world-first attempt to use base editing directly on the brain. The parents, Jason and Linda, funded the trial with their own savings and family contributions, totaling $860,000. The treatment was administered under a regulatory provision that bypasses national approval.

Despite the tragic outcome, the girl's death was never publicly disclosed. An entry on ClinicalTrials.gov remains un-updated, and a related research paper in Nature omitted details about the family and their financial involvement. Experts reviewing the case expressed concerns about the trial's risks being downplayed to the parents and potential safety oversights. This incident highlights ongoing issues with oversight in China's rapidly advancing biotechnology sector, echoing past scandals like that of He Jiankui in 2018.

The parents have come forward to share their daughter's story, seeking accountability. They feel safeguards were inadequate and that the researchers and institutions involved have not been held responsible. The case draws parallels to the death of Jesse Gelsinger in 1999, which significantly impacted early gene therapy research, raising questions about the ethical considerations of testing risky treatments on patients with nonfatal conditions.